eIF2B Activators for Attenuating the Integrated Stress Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for diseases associated with the integrated stress response (ISR) pathway, such as neurodegenerative diseases, leukodystrophies, cancer, inflammatory diseases, and metabolic diseases, are inadequate in modulating the eIF2B activity to effectively attenuate the ISR.
Innovation Solution
Development of compounds that activate eIF2B, specifically those represented by Formulas (I) and (II), to modulate the ISR pathway and treat associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eIF2α is phosphorylated in response to stress signals, then translation initiation is attenuated to help cells cope with stress, but this leads to inadequate modulation of eIF2B activity and failure to effectively attenuate the ISR pathway in disease states
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that bind to eIF2B and allosterically modulate its activity. These compounds serve as mediators between the stress signal and the translation initiation process, enabling fine-tuned control of eIF2B without directly interfering with eIF2α phosphorylation. The compounds bind to specific pockets on eIF2B subunits, inducing conformational changes that enhance GEF activity and promote ternary complex formation, thereby attenuating the ISR pathway in a controlled manner.
Solution Approach 2:
The patent employs parameter changes by modifying the activity level of eIF2B through small molecule binding. The compounds alter the kinetic parameters of eIF2B, specifically enhancing its GEF activity toward eIF2. This changes the equilibrium between phosphorylated and unphosphorylated eIF2 states, allowing the system to adapt its translation initiation rate in response to disease conditions without completely shutting down the stress response.
2Ease of operation
If eIF2B activity is activated to attenuate the ISR pathway, then therapeutic benefits are achieved for various diseases, but this requires precise modulation without completely blocking the stress response
Solution Approach 1:
The patent applies partial action by designing compounds that partially activate eIF2B rather than completely blocking it. The small molecules enhance eIF2B activity to a程度 that is sufficient to attenuate the ISR pathway and provide therapeutic benefit, but not so strong as to completely abolish the stress response. This partial modulation allows the system to maintain homeostasis while treating disease states, achieving the right balance between protection and adaptation.
Data Source
AI summary
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.